viewRevive Therapeutics

Revive Therapeutics to initiate Phase 3 coronavirus trial of Bucillamine in September

The company is pursuing agreements with vendors after receiving FDA approval last week

Coronavirus graphic
The Phase 3 trial will enroll up to 1,000 patients that will be randomized 1:1:1 to receive either 100 mg or 200 mg of Bucillamine three times a day or a placebo for up to 14 days

Revive Therapeutics Inc (CSE:RVV) (OTC:RCCTF) told investors Wednesday that the company is finalizing agreements and aligning resources to initiate a Phase 3 clinical trial of its drug Bucillamine as a treatment for the coronavirus (COVID-19) in September.

The company received approval from the US Food and Drug Administration (FDA) last week to move forward with a trial evaluating the safety and efficacy of the drug in patients with mild-to-moderate COVID-19.

Revive said it plans to engage as many as 10 clinical trial sites in the US and will evaluate potential locations in states including Arizona, California, Florida and Texas.

READ: Revive Therapeutics gets FDA approval to start Phase 3 of possible COVID-19 treatment Bucillamine

The company is also working to secure agreements with vendors regarding project management, medical monitoring, data management and clinical packaging.

“With the FDA approval of the Phase 3 clinical study to evaluate Bucillamine in the treatment of patients with mild-moderate COVID-19, our team and partners are working diligently to align our resources and expertise that will fast-track the Phase 3 study,” CEO Michael Frank said in a statement. 

The Phase 3 trial will enroll up to 1,000 patients that will be randomized 1:1:1 to receive either 100 mg or 200 mg of Bucillamine three times a day or a placebo for up to 14 days. The primary endpoint is the rates of hospitalization and death after four weeks of treatment. 

An interim analysis will be performed by an Independent Data and Safety Monitoring Board (DSMB) after 210 patients have been treated and followed up after the for weeks, after which researchers will select the better performing Bucillamine dose. Patients will then be randomized 2:1 to the selected Bucillamine dose or placebo. Additional interim analyses will be performed after 400, 600, and 800 patients have reached this same four-week threshold.

The firm cautioned shareholders that it is not making any express or implied claims that its product has the ability to eliminate or cure COVID-19 at this time.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

Quick facts: Revive Therapeutics

Price: 0.265 CAD

Market: CSE
Market Cap: $43.45 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Revive Therapeutics named herein, including the promotion by the Company of Revive Therapeutics in any Content on the Site, the Company...


Revive Therapeutics: Analyst sees 'substantial upside potential' as key...

Proactive Research analyst Ed Stacey says Revive Therapeutics (CSE:RVV)(OTCQB:RVVTF) is a speciality life sciences company focussed on repurposing drugs for rare and infectious diseases and has a pipeline of of three main platforms. One of them is Bucillamine (BUC) which is a medication with a...

on 06/30/2020

2 min read